Leo Kim has been involved in biotechnology since his industrial sabbatical at the Royal Dutch Shell Sittingbourne UK laboratory of Nobel laureate Sir John Cornforth. Leo was the R&D director of the Shell/Cetus collaboration which resulted in the Beta (ser) interferon later marketed by Biogen. As CTO of Mycogen, Leo led an international Ag biotech effort resulting in over 700 patents, $450M in sales and R&D operations on several continents resulting in the $1.2B sale to Dow Chemical. Leo was founder, CEO, and Managing director of POSCO BioVentures a $70M venture capital fund investing in companies such as Infinity Pharmaceuticals, Acorda Therapeutics, BioArrays, Geneohm, and PTC. Leo has been on the board of numerous companies. Leo has a Ph.D. from the University of Kansas, was a research associate at MIT and was the highest ranked scientist at Shell Oil.
Recently, Leo has been assembling deal flow through his various sources in the areas of biotechnology, diagnostics, medical devices, digital health and all related healthcare companies. These resources draw upon his contacts since the early 1980’s when there were only a handful of biotechnology companies such as Cetus—now there are over 10,000. His background as a scientist, industry analyst, product development, biotechnology executive, and in venture capital give him a perspective of what winning companies need and look like.